β-arrestin-mediated signaling improves the efficacy of therapeutics

Islam A.A.E.H. Ibrahim, Hitoshi Kurose

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)

Abstract

β-Arrestins (β-arrestin-1 and β-arrestin-2) were first identified as proteins that have the ability to desensitize G protein-coupled receptors (GPCRs). However, it has recently been found that β-arrestins can activate signaling pathways independent of G protein activation. The diversity of these signaling pathways has also been recognized. This leads to an appreciation of β-arrestin-biased agonists, which is a new class of drugs that selectively activate β-arrestin-mediated signaling without G protein activation. In this review, we will discuss the recent advance of β-arrestin-mediated signaling pathways, including a brief account of different biased agonists, their pharmacological applications, and novel β-arrestin research.

Original languageEnglish
Pages (from-to)408-412
Number of pages5
JournalJournal of Pharmacological Sciences
Volume118
Issue number4
DOIs
Publication statusPublished - 2011

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'β-arrestin-mediated signaling improves the efficacy of therapeutics'. Together they form a unique fingerprint.

Cite this